Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
28
MAYNF Quote, Financials, Valuation and Earnings
Last price:
$2.36
Seasonality move
:
-4.45%
Day range:
$2.36 - $2.36
52-week range:
$2.36 - $4.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.72x
P/B ratio:
0.96x
Volume:
--
Avg. volume:
3.7K
1-year change:
-21.52%
Market cap:
$191.7M
Revenue:
$264.3M
EPS (TTM):
-$0.76
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Mayne Pharma Group Ltd. has -- downside to fair value with a price target of -- per share.
MAYNF vs. S&P 500
-
Over the past 5 trading days, Mayne Pharma Group Ltd. has underperformed the S&P 500 by -0.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mayne Pharma Group Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mayne Pharma Group Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mayne Pharma Group Ltd. reported revenues of --.
Earnings Growth
-
Mayne Pharma Group Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mayne Pharma Group Ltd. reported earnings per share of --.
Enterprise value:
212.5M
EV / Invested capital:
--
Price / LTM sales:
0.72x
EV / EBIT:
--
EV / Revenue:
0.79x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$119.6M
Return On Assets:
-11.32%
Net Income Margin (TTM):
-21.8%
Return On Equity:
-26.72%
Return On Invested Capital:
-24.87%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-22 | 2024-12-22 | 2024-12-22 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $313M | $351.9M | $366.5M | $307.9M | -- | |
| Total Assets | $1.1B | $886M | $825.7M | $764.1M | -- | |
| Current Liabilities | $167.2M | $419.9M | $205.8M | $209.8M | -- | |
| Total Liabilities | $519.6M | $502.7M | $405.8M | $460.5M | -- | |
| Total Equity | $579.7M | $383.2M | $419.9M | $303.6M | -- | |
| Total Debt | $253.2M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-22 | 2024-12-22 | 2024-12-22 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
MAYNF
Sector
Market Cap
$191.7M
$27.9M
Price % of 52-Week High
51.3%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.49%
1-Year Price Total Return
-21.52%
-16.66%
Beta (5-Year)
1.872
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.36
200-day SMA
Sell
Level
$3.49
Bollinger Bands (100)
Sell
Level
2.7 - 3.66
Chaikin Money Flow
Buy
Level
21.6K
20-day SMA
Sell
Level
$2.41
Relative Strength Index (RSI14)
Sell
Level
33.67
ADX Line
Sell
Level
25.07
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$3.07
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
51.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.6221)
Sell
CA Score
(Annual)
Level (-0.9579)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.2529)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
Stock Forecast FAQ
In the current month, MAYNF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MAYNF average analyst price target in the past 3 months is --.
-
Where Will Mayne Pharma Group Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mayne Pharma Group Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Mayne Pharma Group Ltd.?
Analysts are divided on their view about Mayne Pharma Group Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mayne Pharma Group Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Mayne Pharma Group Ltd.'s Price Target?
The price target for Mayne Pharma Group Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MAYNF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mayne Pharma Group Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MAYNF?
You can purchase shares of Mayne Pharma Group Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mayne Pharma Group Ltd. shares.
-
What Is The Mayne Pharma Group Ltd. Share Price Today?
Mayne Pharma Group Ltd. was last trading at $2.36 per share. This represents the most recent stock quote for Mayne Pharma Group Ltd.. Yesterday, Mayne Pharma Group Ltd. closed at $2.36 per share.
-
How To Buy Mayne Pharma Group Ltd. Stock Online?
In order to purchase Mayne Pharma Group Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MAYNF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MAYNF
Sector
P/E ratio
--
23.85x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.96x
1.81x
Price / LTM sales
0.72x
1.58x
Growth Metrics
MAYNF
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.5%
Revenue (5-year growth)
-2.91%
6.5%
Earnings forecast
--
-$0.21
Profitability
MAYNF
Sector
Profitability FY 2025
$120.6M
$3.6M
Return on invested capital
-24.87%
-31.87%
Return on assets
-11.32%
-28.18%
Return on equity
-26.72%
-37.63%
Earnings Date
Last Earnings Date
Dec
22
Next Earnings Date
Dec
22
Estimated Next Earnings Date
Mar
23
Balance Sheet
MAYNF
Sector
Total cash
$79.2M
$26.4M
Short term investments
$26.2M
$25.7M
Total assets
$664.9M
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
